Workshop speakers

Rodrigo Alonso

Santiago, Chile

How often do children report statin-related side effects and what can we do about it?

Marcello Arca

Rom, Italy

Apolipoprotein CIII silencing: the benefit in FCS

Maurizio Averna

Palermo, Italy

Familial chylomicronemia syndrome (FCS)

Maurizio Averna was born in Palermo, Italy, in 1952. Degree in Medicine in 1976, University of Palermo, Italy. Specialties in Internal Medicine, Diabetes and Metabolic Diseases, Clinical Biochemistry (1981, 1985 and 1991). Clinical and Research Fellow at the Lipid Research Division, Washington University, St. Louis, U.S.A. (1991-1993).

Full Professor of Internal Medicine, Director of the Residency Program in Internal Medicine, Head of the Unit of Clinical, Respiratory and Emergency Medicine, Head of the Regional Centre of Rare Inherited Metabolic Diseases all at the University of Palermo, Italy

His main interests are biochemistry, genetics and molecular biology of lipids and lipoproteins.

Deepak Bhatt

Boston, USA

The mandate for improving residual CVD risk reduction in patients with persistently elevated LDL-C: What unmet needs still exist among high risk patients across the continuum of ASCVD care? What new outcome - substantiated therapies are in our toolkit?

Getting real world and “hands on” in patients with elevated LDL-C and associated high risk features for ASCVD— interactive case management sessions

Program chair’s 2018 and beyond summary vision statement the data is in: overcoming institutional, cost, and clinical inertia barriers to deployment of non-statin therapies for optimizing treatment and prevention of ASCVD.

Mafalda Bourbon

Lisbon, Portugal

How many “FH” children have polygenic hyperlipidaemia? The Portuguese FH Study register

How to avoid the differential diagnostic odyssey

Agniezska Brandt

Gdansk, Poland

The Poland experience

Alberico L. Catapano

Milan, Italy

Will aggressively lowering of LDL prevent atherosclerosis?

Current concepts and their use in clinical practice

Alberico L. Catapano was born in Milan in 1952. He received his degree from the University of Milan in 1975 and specialization in clinical pharmacology in 1979. Since 1972, Professor Catapano has been involved in the fields of atherosclerosis, lipids, lipoproteins and genetic dyslipidaemias, and has made landmark observations regarding heat shock proteins and pentraxins in atherogenesis, on high-density lipoprotein in the modulation of the immune response, and on the identification of possible therapeutic targets by exploiting genetic information. Alberico Catapano is Full Professor of Pharmacology at the University of Milan, Director of the Laboratory of Lipoproteins, Immunity and Atherosclerosis of the Center for the Study of Atherosclerosis at the “Bassini” Hospital. He is also the Director of the Center of Epidemiology and Preventive Pharmacology of the University of Milan. He is the immediate past President of the European Atherosclerosis Society (EAS) and Chairman of the EAS/European Society of Cardiology (ESC) guidelines for the treatment of dyslipoproteinaemias. He holds board positions on several learned scientific societies, including the Italian Society for the Study of Atherosclerosis. He is also President of the Italian Society of Clinical and Experimental Therapy (SITeCS) and General Director of the SISA Foundation (Italian Society for the Study of Atherosclerosis).

Professor Catapano has authored more than 390 scientific papers in peer-reviewed journals and several books in the area of the atherosclerosis, lipoproteins and lipid metabolism. He is Editor of Atherosclerosis Supplements and also Co-editor of Atherosclerosis and Associate Editor of other scientific journals. According to Google Scholar, his H-index is 67 and the last 5 years has received more than 15,000 citations.

 

Christina Christoffersen

Copenhagen, Denmark

THE APOLIPOPROTEIN M/S1P AXIS CONTROLS TRIGLYCERIDE METABOLISM AND BROWN FAT ACTIVITY

Kristyna Cilikova

Prague, Czech Republic

Barriers and where to seek help in establishing and expanding FH patients´ groups

Guy G. De Backer

Gent, Belgium

Primary prevention of CVD

LIPID MANAGEMENT OF PATIENTS WITH CORONARY HEART DISEASE IN 27 COUNTRIES IN EUROPE: RESULTS OF EUROASPIRE V SURVEY OF THE EUROPEAN SOCIETY OF CARDIOLOGY

Honorary Professor of Medicine, Ghent University, Ghent, Belgium

Guy De Backer graduated in 1968 as medical doctor at the University of Ghent, Belgium. He holds special degrees in cardiology and in cardiac rehabilitation and he was awarded with an additional degree in public health. In 1979 he was awarded with a PhD in epidemiology at Ghent University with a dissertation based on results from the Belgian Heart Disease Prevention Project, part of the WHO European Collaborative Group Project. From 1973 until 1988 he was a permanent research fellow at the National Fund for Scientific Research (Belgium).  

From 1988 onwards he was professor of medicine at Ghent University chairing the Department of Public Health from 1989-2009. At the University Hospital in Ghent he has been chairing the Cardiac Rehabilitation centre from 1983-2009 and the Department of Cardiology from 2007-2009.

He is the author or co-author of 458 publications in journals cited in SCI, SSCI or AHCI, 130 papers in other journals and more than 50 chapters in books. Thomson Reuters 2015:  citations: 31441; h-index 62; ‘highly cited researcher’

Guy De Backer was a member (1994-2016) and the past-chairman (1996-2009) of the Superior Health Council of Belgium and is a member and the past-president (2007-2010) of the Royal Academy of Medicine of Belgium.

Edward A. Dennis

San Diego, USA

Potential and caveats of lipidomics for cardiovascular disease

Professor Dennis is Chair of the Department of Chemistry and Biochemistry and Distinguished Professor of Chemistry, Biochemistry and Pharmacology in the School of Medicine at the University of California at San Diego (UCSD). He graduated Yale University (BA), Harvard University (Ph. D), was a postdoctoral fellow at Harvard Medical School, and received Doctorates in Medicine (honorary) from Goethe University and the University of Lyon INSA. He is Editor-in-Chief of the Journal of Lipid Research and was the Director of the LIPID MAPS Consortium which developed the lipidomics field with over 385 publications on eicosanoids, inflammation, lipidomics, lipid signaling, and phospholipases.

Olivier Descamps

Haine Saint-Paul, Belgium

The Belgium experience

Euridiki Drogari

Athens, Greece

Treatment of children with an FH phenotype caused by mutation in LIPA

Mark Febbraio

Darlinghurst, Australia

Role of TLR4 in lipid induced macrophage inflammation

Prof Mark Febbraio is a SPRF of the NHMRC and the Head of Division, Diabetes & Metabolism at The Garvan Institute of Medical Research in Sydney, Australia. He is the CSO of N-Gene Research Laboratories Inc., a USA based Biotechnology Company and the Founder and CSO of the recently incorporated company Kinomedica. His research focuses on understanding cellular and molecular mechanisms associated with exercise, obesity, type 2 diabetes and cancer.  His aim is to develop novel drugs to treat lifestyle related diseases. He has authored over 230 peer-reviewed papers in leading journals and has over 25,000 career citations.  Prof Febbraio’s most recent prizes include the Sandford Skinner Oration-The University of Melbourne (2011), Eureka Scientific Prize Finalist (2013) and the Australian Diabetes Society Kellion Award (2017).

Brian A. Ference

Cambridge, United Kingdom

Lessons from genetics: risk-score and novel candidates

Validating pharmacological targets by genetics: the case of ATP Citrate Lyase

Lifestyle and genetics an interaction contributing to cardiovascular risk

LPA VARIANTS, RISK OF CORONARY DISEASE, AND ESTIMATED CLINICAL BENEFIT OF LIPOPROTEIN(A) LOWERING THERAPIES: A MENDELIAN RANDOMIZATION ANALYSIS

Apo B containing lipoproteins a better target for CV risk reduction?

Brian Ference is Associate Professor of Medicine, Clinical Chief of the Division of Cardiovascular Medicine and Director of the Cardiovascular Genomic Research Centre at Wayne State University School of Medicine. He is currently on leave from those posts and living in Beijing where he is Chief Medical and Scientific Officer for the Chinese Precision Medicine Initiative US-Sino Collaboration, which is helping to design the next generation healthcare system based on a virtual cloud-based infrastructure and informed by personalized machine learning “prescriptive genomic” testing. Dr. Ference is also a member of the Leadership Council of the American College of Cardiology’s Section on the Prevention of Cardiovascular Disease. Dr. Ference is a cardiologist and genetic epidemiologist who was educated and trained at Harvard, Yale, Oxford and Cambridge Universities. His research focuses on the use of naturally randomized genetic evidence to 1) accelerate the drug discovery and development process by designing and conducting portfolios of “naturally randomized trials”; 2) identify patterns of polymorphism that define differential vulnerability to modifiable cardiovascular risk factors as a strategy to personalize the prevention of cardiovascular disease; and 3) frame and answer important public health questions to fill evidence gaps when an actual randomized trial would be either impossible or impractical to conduct thereby informing (and challenging) cardiovascular medicine treatment guidelines. He holds leadership positions in several international cardiovascular medicine professional societies.

Tomas Freiberger

Brno, Czech Republic

The EAS Homozygous FH register

Phillipe Gabriel

Paris, France

Robert Gerszten

Boston, USA

Mining the blood for new cardiometabolic markers

Robert E. Gerszten, MD is Chief of Cardiology at Beth Israel Deaconess Medical Center, the Herman Dana Professor of Medicine at Harvard Medical School, and a Senior Associate Member of the Broad Institute. Dr. Gerszten’s investigations focus on the nexus of cardiac and metabolic diseases. His translational research program leverages metabolomics and proteomic technologies for the discovery of new biomarkers and pathways contributing to atherogenesis and its complications. His highly interactive program collaborates across a spectrum of institutions, from the Broad Institute to the Framingham Heart Study, the Jackson Heart Study, the Diabetes Prevention Program, and the TIMI Study Group.

Stephan Gielen

Halle, Germany

Will inhibiting thrombus formation prevent acute coronary syndromes?

As President of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR) 2012-14, as National CVD Prevention Coordinator for Germany, and as Secretary of the Project Group on Prevention of the German Cardiac Society Stephan Gielen has been active in cardiovascular prevention. He works as Director of the Dept. of Cardiology, Angiology, and Intensive Care Medicine at the Klinikum Lippe, Detmold, Germany and is member of the Medical Faculty of the Martin-Luther-University Halle-Wittenberg, Germany. He is editor of the ESC Textbook of Preventive Cardiology, co-author of the ESC Textbook of Cardiovascular Medicine and author/coauthor of more than 150 peer-reviewed scientific articles.

Diedrick Grobbee

Utrecht, The Netherlands

Early therapy versus late intervention; what works?

Diederick Grobbee is Professor of Clinical Epidemiology, Founder of the Julius Center, University Medical Center Utrecht. He is CSO of Julius Clinical, full service Academic CRO, Previously Professor of Clinical Epidemiology Erasmus University and Associate Professor Harvard University. Professor Grobbee has Honorary appointments in Sydney and Kuala Lumpur. He is listed in the top 100 global most influential biomedical researchers (Eur J Clin Invest 2013), Senior-consulting-editor European Journal of Preventive Cardiology (previously editor-in-chief), President European Association of Preventive Cardiology, Distinguished University Professor of International Health Sciences and Global Health (Utrecht University).

He is Fellow of the Royal Dutch Academy of Sciences and was Knighted by the Dutch King (2017). Professor Grobbee has published more than 1330 scientific papers and has an H-index (WoS) of 138.

Albert K. Groen

Groningen, The Netherlands

The role of bile acids in cholesterol homeostatis

Bert Groen is professor of Systems Biology and Medicine at both AMC, Amsterdam and UMCG, Groningen, The Netherlands. His research focuses on understanding the molecular regulation of metabolic pathways involved in bile salt, lipid and carbohydrate metabolism. Bert’s group discovered a novel pathway for cholesterol secretion; directly from the blood to the intestinal lumen. They called this pathway transintestinal cholesterol secretion (TICE). Realizing ever more the extreme complexity of regulation of metabolism in humans including the influence of the intestinal microbiome, the focus of Bert’s group shifted recently to a novel emerging field of biomedical research; systems biology and systems medicine.

Joachim Herz

Dallas, USA

Lipoprotein metabolism in the brain

Joachim Herz, MD, is a Professor of Molecular Genetics, Neuroscience, Neurology and Neurotherapeutics at the University of Texas Southwestern Medical Center at Dallas.  His research focuses on the mechanisms by which Apolipoprotein E, the primary genetic risk factor for late-onset Alzheimer’s disease and a ligand for members of the LDL gene family, predisposes to synaptic dysfunction and neurodegeneration. The Herz Lab aims to determine whether altering ApoE expression and trafficking could eventually be a viable therapeutic option for treating Alzheimer’s disease, in addition to providing new insights into mechanisms leading to fatty liver, insulin resistance and atherosclerosis.

Steve Humphries

London, UK

The UK register statin clinical decision support tool

Takeshi Kimura

Kyoto, Japan

Evidence from REAL-CAD

Ulrich Laufs

Homburg, Germany

Reality check: Can we get to goals in guidelines?

In July 2017, UL was appointed as the Professor of Cardiology at Leipzig University and as chairman of cardiology at Leipzig University Hospital.

Ulrich Laufs was born in Göttingen, Germany, and studied philosophy and medicine in Bochum. He completed his training at the University of Hamburg, where he did his medical thesis at the Institute of Pharmacology. After his residency at the University of Köln he worked for 2 years at the Cardiovascular Division of the Brigham and Women´s Hospital in Boston. In the lab of Jim Liao he described the cholesterol-independent regulation of endothelial nitric oxide synthase by statins, a mechanism that contributes to the effects of statins on ischemic stroke. Under the mentorship of Michael Böhm he undertook his fellowships at the University of Köln and the University of Saarland.

Before his recent move to Leipzig, Ulrich Laufs was Professor for Clinical and Experimental Medicine and served as Vice Chairman of the Department of Internal Medicine, Cardiology, Angiology and Intensive Medicine at the University of Saarland, Homburg, Germany. He has received numerous honours including a first place of the Young Investigator Award of the American College of Cardiology, the Population Sciences Award of the European Society of Cardiology, the Paul-Martini-Award, and the Albert-Fraenkel-Award of the German Cardiac Society. UL serves in serveral editorial boards and as a member of the federal drug commissions of the German Physicians (Arzneimittelkommission der Deutschen Ärzteschaft, AkdÄ) and the German Pharmacists (Arzneimittelkommission der Deutschen Apotheker, AMK). He is chairman / member of the nucleus of the working groups on “heart failure”, “heart and brain” and on “prevention” of the German Society of Cardiology.

Professor Laufs works as interventional cardiologist. He has a special clinical interest in lipid disorders and heads a research group with special focus on the cellular and molecular mechanisms and clinical studies of cardiovascular prevention. UL enjoys the combination of acute and interventional patient care with cardiovascular prevention and translational research. His current research is focused on

  • Vascular biology, ischemic stroke and cardiovascular prevention.  His group has a special interest in the study of the molecular effects of physical exercise, such as the molecular regulation of cellular senescence.
  • Clinical and experimental research in lipid metabolism. The group has characterized several cholesterol-independent effects of statins mediated by isoprenylation of small G proteins. Currently his group is interested in the cellular actions of triglycerides, plant sterols, PCSK9 and ApoCIII.
  • Pathophysiology of myocardial remodelling and fibrosis. UL headed a research consortium funded by the Deutsche Forschungsgemeinschaft (DFG) that elucidates the signalling during adaptive and maladaptive myocardial remodelling, a topic that is closely related to his projects addressing small G protein function and physical exercise.
  • Cardiovascular pharmacotherapy. The clinical trial unit of his research group conducts investigator initiated studies with a special interest in topics related to medication adherence and participates in many multi-center trials.

Nicholas J. Leeper

Boston, USA

The role of efferocytosis in atherosclerosis

Dr. Nicholas Leeper is a vascular biologist and cardiologist interested in atherosclerosis and aneurysm disease. His laboratory pursues these conditions with a combination of translational approaches from the fields of human genetics, molecular biology, and murine models of vascular disease. They hope to translate their findings from bench to bedside to reduce the burden of cardiovascular disease. A specific example of this work centers in their recent discovery of the role of efferocytosis (the phagocytic clearance of apoptotic debris) in the heritable component of atherosclerosis. He also directs the Stanford Vascular Medicine Translational Research Program, which works towards targeting these processes in humans with cardiovascular disease.

Ziad Mallat

Cambridge, United Kingdom

Functional immune cell interactions and plaque development

Dr. Mallat received his MD and qualification in Cardiovascular Diseases from University of Pierre et Marie Curie in 1996, and his Ph.D. in Vascular Biology, Thrombosis and Haemostasis from University of Paris-Diderot in 1999. He joined INSERM, Paris in 1998 as Assistant Research Professor, became Associate Professor in 2002 and Research Professor in 2007. He is currently BHF Professor of Cardiovascular Medicine at the University of Cambridge, UK. He is Associate Editor of Arteriosclerosis Thrombosis and Vascular Biology, Atherosclerosis, and British Journal of Pharmacology on the Editorial Board of Circulation Research, Journal of Molecular Medicine, and JCI Insight.

Adil Mardinoglu

Stockholm, Sweden

Nonalcoholic liver hepatic steatosis: a systems biology approach

Dr. Mallat received his MD and qualification in Cardiovascular Diseases from University of Pierre et Marie Curie in 1996, and his Ph.D. in Vascular Biology, Thrombosis and Haemostasis from University of Paris-Diderot in 1999. He joined INSERM, Paris in 1998 as Assistant Research Professor, became Associate Professor in 2002 and Research Professor in 2007. He is currently BHF Professor of Cardiovascular Medicine at the University of Cambridge, UK. He is Associate Editor of Arteriosclerosis Thrombosis and Vascular Biology, Atherosclerosis, and British Journal of Pharmacology on the Editorial Board of Circulation Research, Journal of Molecular Medicine, and JCI Insight.

Miguel Angel Martínez-Gonzalez

Navarra, Spain

The nutritional advice in daily practice and the pyramid of the Mediterranean diet: can we be effective in the long term?

Luis Masana

Reus, Spain

Incremental value of established therapies for dyslipidaemic patients

R. Preston Mason

Beverly, MA, USA

EICOSAPENTAENOIC ACID INHIBITED OXIDIZED HDL-INDUCED LOSS OF ENDOTHELIAL NITRIC OXIDE RELEASE AS COMPARED TO FENOFIBRATE OR NIACIN IN VITRO

Manuel Mayr

London, United Kingdom

Systems biology-opportunities and challenges: the application of proteomics to study the cardiovascular extracellular matrix

Dr. Mallat received his MD and qualification in Cardiovascular Diseases from University of Pierre et Marie Curie in 1996, and his Ph.D. in Vascular Biology, Thrombosis and Haemostasis from University of Paris-Diderot in 1999. He joined INSERM, Paris in 1998 as Assistant Research Professor, became Associate Professor in 2002 and Research Professor in 2007. He is currently BHF Professor of Cardiovascular Medicine at the University of Cambridge, UK. He is Associate Editor of Arteriosclerosis Thrombosis and Vascular Biology, Atherosclerosis, and British Journal of Pharmacology on the Editorial Board of Circulation Research, Journal of Molecular Medicine, and JCI Insight.

Samia Mora

Boston, USA

High-resolution lipoprotein phenotypes and cardiovascular outcomes

Samia Mora, MD, MHS is Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts, and Director of the Center for Lipid Metabolomics, Brigham and Women’s Hospital. Dr. Mora received her undergraduate and medical degrees from Harvard University, and completed her cardiology training at Massachusetts General Hospital and Johns Hopkins Hospital. A fellow of the American Heart Association and the American College of Cardiology, Dr. Mora has clinical and research interests in cardiovascular prevention. She serves on the Editorial Board of JAMA Internal Medicine. She has authored many peer-reviewed publications in connection with her research on risk factors and prevention of cardiovascular disease.

Willem J.M. Mulder

New York/ Amsterdam, USA / The Netherlands

Nanomedicine as novel atherosclerosis thearpy

Dr. Mulder is a Professor at Icahn School of Medicine at Mount Sinai as well as at the Academic Medical Center of the University of Amsterdam. His research – funded by several NIH grants and an NWO Vidi – focuses on precision imaging and targeted therapy in cardiovascular disease and cancer. This involves library technology, encompassing nanomaterials derived from natural lipoproteins (nanobiologics), that allows meticulously designing targeted immunotherapies. When appropriately designed, such nanobiologics can be applied to empower the immune system’s ability to fight disease, by promoting or inhibiting an immune response, by polarizing macrophage function, or by targeting myeloid cell dynamics.

Giuseppe Danilo Norata

Milan, Italy

PCSK9/LDLR axis in pancreatic function

Giuseppe Danilo Norata, PhD, is Associate Professor of Pharmacology at the University of Milan, Italy and Adjunct Professor at the School of Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Australia. He graduated in Pharmacy, received the PhD in Experimental  Medicine at the University of Siena and was a post-doc at the Karolinska Institute in Stockholm. His research activity is devoted to the investigation of molecular mechanisms involved in vascular and cardiometabolic diseases and their connection with immunometabolism from a translational perspective. He published more than 145  papers in the field of cardiovascular and immunometabolic  diseases.

Gary K. Owens

Charlottesville, USA

Vascular smooth muscle cells in atherosclerosis

Jules Payne

Maidenhead, UK

HEARTUK and FH-Europe Patient Network initiatives – what information do children want?

Kristina Petersen

Pennsylvania, USA

Fausto J. Pinto

Lisbon, Portugal

Reality check: Guidelines versus real life after ACS

Professor Pinto is Dean of the Faculty of Medicine at the University of Lisbon, Portugal; Head of the Cardiology and Heart and Vessels Department at University Hospital Sta. Maria/CHLN in Lisbon, Portugal, Immediate Past-President of European Society of Cardiology (ESC), Fellow and Gold Medal of the European Society of Cardiology (FESC), Fellow of the American College of Cardiology (FACC), Society for Cardiac Angiography and Interventions (FSCAI) and American Society of Echocardiography (FASE) and he is Honorary member of several international scientific societies around the world.

Matteo Pirro

Perugia, Italy

Lipid-modifying effects of nutraceuticals: an evidence-based approach

Michael Potente

Bad Nauheim, Germany

Transcriptional control of endothelial energy

Michael Potente is a research group leader at the Max Planck Institute for Heart and Lung Research. He is a board-certified cardiologist who was trained at the Universities of Frankfurt and Toronto. He has received several awards including the Louis N. and Arnold M. Katz Basic Research Prize as well as the Albert Fraenkel Prize granted by the German Cardiac Society. In 2014, he was selected for the prestigious EMBO Young Investigator Programme. His work focuses on metabolic adaptations in endothelial cells, aiming to understand how changes in endothelial metabolism impact vascular differentiation and function.

Um Ramaswami

London, UK

The IAS Pediatric FH Register - cross country comparison of baseline characteristics

Kausik Ray

London, United Kingdom

Familial hypercholesterolaemia

EFFECT OF AN RNAI THERAPEUTIC TARGETING PCSK9 ON ATHEROGENIC LIPOPROTEINS: PRE-SPECIFIED SECONDARY ENDPOINTS IN ORION 1

Kausik Ray is Professor of Public Heath, and Honorary Consultant Cardiologist at Imperial College London. Professor Ray received his medical education at the University of Birmingham Medical, his MD thesis at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and his MPhil in epidemiology from the University of Cambridge.A Fellow of the ACC, ESC, AHA, and the RCP (London and Edinburgh).

His research interests have focused on the prevention of CVD from large scale observational studies to clinical trials. His work has influenced international guidelines and received more than 12 000 citations.

Professor Ray leads the EAS FH Studies collaboration involving around 60 countries currently and serves on the Executive Committee of several ongoing trials in cardiovascular disease.  

Rens Reeskamp

Amsterdam, The Netherlands

A DEEP INTRONIC VARIANT IN LDLR CAUSING FAMILIAL HYPERCHOLESTEROLEMIA: TIME TO WIDEN THE SCOPE?

Gabriele Riccardi

Naples, Italy

Dietary fat vs Carbohydrates

Jeanine Roeters van Lennep

Rotterdam, Holland

The Dutch experience (Wat is Dat?)

Stefano Romeo

Gothenburg, Sweden

Genes can hurt you to develop CVD-beyond classical risk factors

Emilio Ros

Barcelona, Spain

Lessons from the "Prevention with mediterranean Diet" (Predimed) study

Why does the diet rich in unsaturated fat protect against cardiovascular disease? Differences between nuts and extra virgin olive oil

Former director, Lipid Clinic, Endocrinology Service, Hospital Clínic, Barcelona; Emeritus Investigator IDIBAPS; PI of research group, CIBER Fisiopatología de Obesidad y Nutrición, Instituto de Salud Carlos III, Spain. Postgraduate training in New York and Boston (1970-1976). American Boards of Internal Medicine and Gastroenterology. Member of Spanish Atherosclerosis Society (SEA), EAS, IAS, ISSFAL, and ACC. Various awards to best scientific career in Nutrition. Research in nutrition for CVD prevention, including Mediterranean diet (PREDIMED trial), walnuts and phytosterols; cognitive function; membrane fatty acids; genetic dyslipidemias; cardiovascular risk assessment; vascular imaging. Publications: over 340 original papers and 125 review papers in peer-reviewed journals.

Lars Rydén

Stockholm, Sweden

Should the main target be hyperglycaemia or should we focus on other risk-factors?

Lars Rydén is Senior Professor of Cardiology at the Karolinska Institute, Stockholm, Sweden. He specialises in internal medicine and cardiology, focussing on arrhythmias, cardiac pacing, heart failure and diabetes-related cardiovascular disease. He has published more than 700 scientific papers. Lars Rydén is Dr h.c. at Katowice University, Poland, and an honorary member of the Royal College of Physicians, UK. Professor Rydén was the President of the Swedish Cardiac Society and chaired the Scientific Board of the Swedish Heart Lung Foundation. He was the President of the European Society of Cardiology (ESC), and served on the board of the World Heart Federation. He chaired ‘Alert’ (a system for identification and early assessment of new methods in healthcare) for the Swedish Council on Technology Assessment in Health Care.

Lars Rydén has chaired numerous expert groups in collaboration with the European Society of Cardiology and European Commission, and on their behalf he chaired the group that produced the European Heart Health Charter and The Chronic Disease Alliance – A Unified Prevention Approach. Professor Rydén chaired the Task Forces of the 2007 and 2013 ESC/European Association for the Study of Diabetes (EASD) Guidelines for Diabetes, Prediabetes and Cardiovascular Disease.

Raul Santos

Sao Paulo, Brazil

FH Children in Brazil

Naveed A. Sattar

Glasgow, United Kingdom

Should the main target be hyperglycaemia or should we focus on other risk-factors?

Naveed Sattar is Professor of Metabolic Medicine at the University of Glasgow. He is a clinically active academic experienced in biomarker studies investigating the causes, prevention and management of diabetes, obesity and heart disease. He has authored or co-authored more than 700 published papers, received several national and international prizes for his research, and is in the top 1% of cited clinical academics. He has been on several national and international guideline committees, including ESC Task Force to develop 2019 Guidelines on diabetes, pre-diabetes, and cardiovascular diseases.

He is currently involved in several lifestyle and drug trials in diabetes and CVD and leads on biomarker initiatives in other trials. He is also on various editorial and international advisory boards and is an Associate Editor for Circulation.

Heribert Schunkert

Munich, Germany

Genes can protect you from CVD – beyond classical risk factors

Heribert Schunkert, MD is Professor of Cardiology of the Technische Universitaet Munich, Director of the Cardiology Department, German Heart Centre Munich. He completed a research fellowship at Brigham and Women’s Hospital, Boston, USA and clinical fellowships at Beth Israel Hospital and at the Universitaetsklinikum, Regensburg and the Massachusetts General Hospital, Boston, USA. From 2002-2012 Prof. Schunkert was Director of Internal Medicine and Cardiology at the University of Luebeck. He conducts research in the molecular genetics of multifactorial cardiovascular disease, coordinates several EU- and BMBF-sponsored projects as well as the European-American Leducq network CADgenomics to identify the genetic roots of myocardial infarction. He is the author of more than 600 publications in international journals.

Eleonora Scorletti

Southampton, United Kingdom

Omega 3 fatty acids & hepatic lipid metabolism

Peter Sever

London, United Kingdom

PCSK9 inhibition the clinical evidence

Gabriel P. Steg

Paris, France

PCSK9 inhibition in high risk patients

What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us? How safe and effective are PCSK9 inhibitors and in whom and when should they be deployed?

Getting real world and “hands on” in patients with elevated LDL-C and associated high risk features for ASCVD— interactive case management sessions

Erik S. Stroes

Amsterdam, The Netherlands

Very high risk patient - secondary treatment

Lipids, inflammation and cardiovascular risk

Secondary prevention: can we go further?

Erik Stroes received his medical degree from the University of Rotterdam in 1991, and subsequently was trained in internal medicine at the University Medical Center of Utrecht.

In 2001 he completed his Vascular Medicine specialization and continued his career as staff member of the Vascular Medicine department at the Academic Medical Center in Amsterdam, currently serving as a tertiary referral center for over 1500 patients each year. He is currently professor of Vascular Medicine. Professor Stroes has a particular interest in lipid disorders in relation to atherogenesis and has participated in numerous lipid lowering trials. He is (co)author of more than 350 scientific publications associated with his research interests. He is coordinator of 2 European grants, relating to epigenetics and cardiovascular risk assessment using proteomics.

Filip K. Swirski

Boston, USA

Distant control of plaque formation

Dr. Filip Swirski is the Patricia and Scott Eston MGH Research Scholar, Principal Investigator at Massachusetts General Hospital’s Center for Systems Biology, and Associate Professor at Harvard Medical School. Dr. Swirski’s research aims to understand how innate leukocytes such as monocytes and macrophages shape and are shaped by inflammation.

Alan Tall

New York, USA

Clonal hematopoiesis in atherosclerosis

Alan Tall is the Tilden-Weger-Bieler Professor of Medicine and head of the Division of Molecular Medicine at Columbia University.  Dr. Tall discovered mutations in the cholesteryl ester transfer protein (CETP) gene that are associated with increased HDL levels and reduced LDL levels and identified CETP as a therapeutic target.  He elucidated the role of ABCA1 and ABCG1 in regulating the proliferation of hematopoietic stem cells and the production of myeloid cells and platelets. Recently he has focused on understanding the mechanisms underlying the association of human genetic variants  with atherosclerosis.  He has been awarded the Irvine Page Award, the Robert I. Levy Lectureship, the Distinguished Scientist Award (AHA) and the Anitschkow Prize.

Lale Tokgozoglu

Ankara, Turkey

Multimodality imaging is the way to go

Science versus reality in long term management: Time for a paradigm shift?

S. Lale Tokgözoğlu, M.D., F.A.C.C., F.E.S.C. was born in 1959 in Ankara, Turkey. She graduated from the Hacettepe University Faculty of Medicine in 1982 on the honor roll. After finishing the Internal Medicine Residency program in the Hacettepe University Faculty of Medicine Department of Internal Medicine on 1988, she completed a fellowship program on Cardiology and Atherosclerosis at the Baylor College of Medicine in Houston, Texas. Dr. Tokgözoğlu returned to the Hacettepe University in 1991 to become Associate Professor of Cardiology, and later Professor of Cardiology in 1998.

Prof. Tokgözoğlu has served on the Executive Committee of the European Society of Atherosclerosis as member between 2003 and 2005 ,as Secretary between 2005-2009 and as Vice President of the European Atherosclerosis Society between 2009-2013. She is currently President-elect of the European Atherosclerosis Society. She was the President of the 77th European Atherosclerosis Society meeting in İstanbul.

She also served as the President of the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010.  She has served for 2 years on board of the European Society of Cardiology Fellowship and Training Committee and for 2 years on the board of the Education Committee. She has also served first as Member-at-Large (Europe) of the Executive Committee of the International Society of Atherosclerosis, then as President of the European Federation of the International Atherosclerosis Society followed by the post of  Secretary of the International Society of Atherosclerosis. She is still serving on their executive committee.

Prof. Tokgözoğlu has served on the Board of the Prevention Association of the European Society of Cardiology since 2011. She will be the chair of the Europrevent Congress in 2016 in İstanbul. Prof Tokgözoğlu has founded and chaired the Istanbul Consortium Chapter of the American College of Cardiology in 2010 which is a consortium of 16 countries. She was elected to be the European representative of the American College of Cardiology Assembly of International Governors Steering Committee in 2015.

She has been serving on the Scientific Program Committee of European Society of Cardiology since 1995. She has been a member of the young investigator award committees of the International Atherosclerosis Society in Stockholm 2000,  European Atherosclerosis Society in Prague in 2005 and European Society of Cardiology in 2009, 2010 and 2015. Prof. Tokgözoğlu is currently a Fellow of the American College of Cardiology and European Society of Cardiology.

Prof. Tokgözoğlu has been elected to the ‘Science Academy in Turkey’ in 2014. Prof. Tokgözoğlu has served as the Secretary of the Lipid Working Group of the Turkish Society of Cardiology between 1994 and 1996, as President of the Lipid Working Group of the Turkish Society of Cardiology between 1998 and 2000. She has been on the Executive Committee of the Turkish Society of Cardiology for 6 years between 2000 and 2006 and  as  Vice President between 2008 and 2010 and is currently the President of the Turkish Society of Cardiology.  

She has chaired the ‘Research Committee of the Turkish Society of Cardiology’ for 4 years. She is the founding member of the Atherosclerosis Research and Education Society in Turkey. Prof  Tokgözoğlu is one of the authors of the ‘National Heart Health Policy’ for Turkey.

Prof Tokgözoğlu initiated the academic collaboration between Cornell-Weill Medical College and Hacettepe Universities in 2013 and is the Coordinator for the Cornell-Weill Medical College affairs in Hacettepe University.

Prof Tokgözoğlu has more than 200 publications, has authored 3 books and several book chapters. Prof. Tokgözoğlu is on the Editorial Board for European Heart Journal, Atherosclerosis, Anatolian Journal of Cardiology and Archives of the Turkish Society of Cardiology.  She has won the “Prof. Dr. Şeref Zileli “Resident of the Year” Award in 1987; the Sandoz Scientific Award in 1989 and the “Young Investigator Award” of the Turkish Society of Cardiology in 1994 and second runner up in the Pfizer Cardiology Scientific Award in 1999.

Prof Tokgözoğlu works and publishes on atherosclerotic vascular disease, clinical lipidology, imaging ,hypertension and pulmonary hypertension.

Peter Tontonoz

Los Angeles, USA

Lipid signaling pathways in physiology and disease

Peter Tontonoz is the Frances and Albert Piansky Professor of Pathology and Laboratory Medicine at the University of California, Los Angeles. The focus of his laboratory is the control of gene expression by lipids and the role of nuclear receptors in lipid metabolism. Dr. Tontonoz has helped to elucidate fundamental mechanisms by which animals maintain cellular and whole-body lipid homeostasis. He is a recipient of the Weitzman and Aurbach Awards from the Endocrine Society, and the Jeffrey Hoeg Award from the AHA. He serves on a number of editorial boards and is Editor in Chief of Molecular and Cellular Biology. 

Sotirios (Sam) Tsimikas

San Diego, USA

Are we ready to test the Lp(a) hypothesis?

Silencing genes, new targets

Dr. Tsimikas is Professor of Medicine and Director of Vascular Medicine at the University of California San Diego. He obtained his MD degree in 1988 from the University of Massachusetts Medical School. He completed Internal Medicine training at the University of Massachusetts Medical Center in 1991, and fellowships in Cardiovascular Disease, Atherosclerosis and Molecular Medicine and Interventional Cardiology at the University of California San Diego from 1992-1997. Dr. Tsimikas’ clinical interests Vascular Medicine Program encompass treating patients in the continuum of high-risk primary prevention to endovascular intervention.

Anne Tybjaerg-Hansen

Copenhagen, Denmark

The Anitschkow Lecture - Genetics of cardiovascular disease: From ugly duckling to beautiful swan

Anne Tybjærg-Hansen MD DMSc, is Chief Physician at the Department of Clinical Biochemistry, Section for Molecular Genetics, at Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (since November 1999), as well as Professor of Clinical Biochemistry with Focus on Translational Molecular Cardiology at the University of Copenhagen, Copenhagen, Denmark (since December 2009). She graduated as a medical doctor from the University of Copenhagen in 1981 and her scientific education included one year at the University of Copenhagen and the Lipid Clinic at Righospitalet, 3 years at Hagedorn Research Laboratory, Gentofte, Denmark; and 3 years at the British Heart Foundation’s Molecular Biology Research Group, London, UK.

Professor Tybjaerg-Hansen is a member of the steering committees of the Copenhagen City Heart Study and the Copenhagen General Population Study and past chairman of the European Lipoprotein Club.

Jan M. van Deursen

Rochester, USA

Senescent intimal foam cells are deleterious at all stages of atherosclerosis

Dr. Jan van Deursen received his Ph.D. in Cell Biology at the University of Nijmegen in 1993. He started his own lab at St Jude’s Children’s Research Hospital in 1996.  He joined Mayo Clinic in 1999, where he is currently a Professor and Chair of the Department of Biochemistry and Molecular Biology and Professor of Pediatrics and Adolescent Medicine.  He is the Vita Valley Named Professor of Cellular Senescence and directs the Cell Biology program of the Mayo Clinic Comprehensive Cancer Center, and the Mayo Clinic Gene Knockout and Transgenic Core Facility.

Nick J. Wareham

Cambridge, United Kingdom

How to combat CVD at a population level?

Gerald Watts

Perth, Australia

The Australia experience

Albert Wiegman

Amsterdam, Holland

At what age should we consider a statin or PCSK9 and what should our LDL-C target be?

Seppo Ylä-Herttuala

Kuopio, Finland

Cardiovascular gene therapy

Dr. Yla-Herttuala is a world leader in cardiovascular gene therapy for atherosclerosis and ischemic diseases. His team was the first to use adenovirus-mediated gene transfer to human arteries already in 1995. Since then, he has conducted eight phase 1-3 clinical trials in cardiovascular gene therapy. He is also the originator of the concept of epigenetherapy. His group has been widely recognized for basic biology, translational and epigenetic research of the vascular endothelial growth factors, especially focusing on the new members of the VEGF family. Previously he worked with oxidized LDL and atherosclerosis and was the first to show that OxLDL exists in human atherosclerotic lesions. His list of publications includes over 500 scientific articles.

José Luis Zamorano

Madrid, Spain

LDL after ACS: How low to go? How to go there?

Hospital management after acute coronary syndromes: Is the risk over?

José Zamorano is Head of Cardiology at University Hospital Ramón y Cajal in Spain. He received his medical degree from Complutense University of Madrid (UCM) in 1987 and graduated as a Doctor in Medicine with distinction in 1991. Professor Zamorano subsequently received board certification in Cardiology in 1993 and become an Associate Professor at UCM. He has since received fellowships from both the Spanish and European Societies of Cardiology and an honorary fellowship from the American Society of Echocardiography. A prominent figure in the field of cardiac imaging, particularly echocardiography, Professor Zamorano has been Secretary of the European Society of Cardiology (ESC), President of the European Association of Echocardiography (EAE), Chair of the ESC Guidelines, and is currently Chair of the ESC Global Affairs Committee. He serves on the editorial board of almost 20 scientific journals, including European Journal of Echocardiography, European Journal of Cardiovascular Medicine, World Journal of Cardiology and European Heart Journal.

Professor Zamorano has received numerous awards for his research into techniques used in patients with heart failure and ischaemic heart disease, including the the ESC Silver Medal in 2010. He has made a considerable contribution to the scientific literature, including over 345 publications in peer-reviewed journals, more than 400 abstracts presented at congresses and 62 chapters in medical textbooks.

Antonis Zampelas

Athens, Greece

Clinical trials in evaluating OMEGA 3 fatty acids in CV disease